Health Check: Compumedics claims world first ‘kids eat for free' brain scanning breakthrough
Compumedics' MEG unit can scan adult and kid's heads at the same time – a technically tricky task
Microba's comprehensive gut testing reveals all is not well in the tummy region
Trump's drug pricing blitz should be 'immaterial', says Telix
Brain-scanning specialist Compumedics (ASX:CMP) reports a world's first: decent concurrent readings from both adult and children patients imaged by the same MEG device at China's Tianjin Normal University.
It's like the old Smorgy's: kids eat for free.
MEG stands for magnetoencephalography, a non-invasive neuroimaging technique that maps brain activity by recording magnetic fields produced by electrical currents in the grey matter.
The problem to date is that the head scanners on MEGs haven't been compatible with young and adult noggins, which require two separate units.
Many MEG measurements are done on kids, especially for epilepsy diagnostics.
Compumedics' Orion Lifespan MEGs rectify this this with a two-scanner configuration (the scanner look like old-fashioned hair dryers at a salon).
'A key principle of MEG is that because magnetic fields drop off very rapidly with distance, the sensors should be as close as possible to the sources of the brain signals,' the company says.
'Since the sensors must be within a rigid helmet shape, a child's small head in an adult size helmet results in sensors far from the brain.'
Orion Lifespan MEGs also enable better cooling – resulting in more sensitive measurements – and full recycling of the expensive coolant, liquid helium.
This enables around-the-clock use of the units.
Tianjin Normal University was the first of four Chinese institutions to buy an Orion MEG.
In March this year Compumedics sold its fourth unit, to Hangzhou Normal University in a $5.7 million deal.
The orders to date account for about $20 million of revenue.
Compumedics founder and executive chair Dr David Burton says the company has spent 'many millions' over the last decade to perfect the units.
Currently, about 200 MEGs are used globally.
Burton reckons eventually there should be just as many MEGs as magnetic resonance imaging units – and there are 34,000 of the latter in use.
Microba says we've all had a gutful
An expansive study carried out by microbiome specialist Microba Life Sciences (ASX:MAP) suggests our tummies are not in the best of shape, but the ailments can be rectified with better clinical management.
The company analysed 4600 patient results from its Metaxplore tests, which scan for 28,000 microbial species in the lower intestine.
Some of these bugs are friendly and some of them are pathogenic.
In more than 70% of cases, the preliminary results showed abnormalities in gut bacteria, signs of infection or inflammation markers "that could inform targeted treatment strategies".
More than 42% of the tests showed microbiome markers linked to gastrointestinal health, while close to 10% exhibited symptoms such as inflammation, pancreatic insufficiency and blood in stools.
Microba's selling point is that 65% of patients reported an improvement after following 'clinically directed recommendations informed by Metaxplore".
The test can help clinicians to apply "personalised, multi-dimensional treatment plans to support the clinical management of patients with chronic and functional lower gastrointestinal disorders'.
Even the tests identifying no problems can be helpful in terms of ruling out causes. In some cases, they may point to 'psychological or neurological contributors' to symptoms.
In its March quarter update, Microba reported revenue of $3.4 million, down 14% . But management guided to full-year turnover of $15.25-16.25 million, 26-34% higher.
Microba doubled sales of Metaxplore tests during the stanza, to 3225, taking the annualised run rate to 12,900 units.
Locally the assays sell for $369 a pop.
Telix shrugs off Trump drug pricing threat
Telix Pharmaceuticals (ASX:TLX) has declared the Trump administration's proposed move to lower prescription drug prices has a 'a low likelihood of material impact' on the nuclear medicine group's business.
The key reason is the unique nature of radiopharmaceuticals, which rely on a complex supply chain and 'just-in-time' manufacturing.
In other words: the isotopes used on US patients need to be made in the US because of short half lives.
The ready-to-inject radioactive doses are delivered through local nuclear pharmacy distributors.
Under its most favoured nation decree, The Trump administration plans to benchmark local drug prices against those charged in the cheapest of the industrialised nations.
The Prez claims this will reduce drug prices by up to 80% and save Medicare a poultice of money.
But Telix says its localised production makes international pricing comparisons "challenging to benchmark".
Telix derives most of its revenue in the US, from its approved prostate cancer imaging agent Illucix.
The company intends to go ahead with commercialising kidney and brain cancer imaging products – Zircaix and Pixclara respectively – and advance cancer therapy agents.
The company promises 'pharmaco-economically defensible' pricing in the US.
Telix's comments were by way of a news item on its website, rather than an ASX announcement.
OIL say! – that's a decent share rise
Today's biotech winner is Optiscan (ASX:OIL), with its shares bounding three cents – 30% – in initial trade.
Optiscan had nothing fresh to report, but yesterday said a robotic surgery development effort with Mayo Clinic was going well.
Specifically, the venture is about incorporating Optiscan's digital confocal laser endomicroscopic (CLE) imaging in the robotic system.
The robots do the fiddly work, while the surgeons guide via joystick (not even necessarily in the same room).
The robots have a steadier hand – and often a better bedside manner.
Rather than wait for biopsies, the CLE enables a real-time assessment in terms of cancer cell types and the extent of the margins at the edge of the tumour.
'This capability is expected to streamline surgical workflows, enhance decision-making, and reduce the likelihood of follow-up surgeries,' the company says.
Optiscan CEO Dr Camile Farah says the venture – initially aimed at breast surgery – has 'materially progressed'.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
4 hours ago
- News.com.au
Toyota makes startling comments about EVs
One of the world's biggest automakers has made several startling comments about electric vehicles (EVs). Toyota Chairman Akio Toyoda doubled down on his belief that hybrids, not EVs, are the smarter and more sustainable option in many parts of the world. In a recent interview, the grandson of Toyota Motor's founder made a claim: that the brand's 27 million hybrid cars have delivered the same carbon-cutting effect as 9 million battery electric vehicles (BEVs). But in countries like Japan, where electricity largely comes from thermal (fossil fuel) power plants, he said making those same BEVs could have actually increased emissions. 'If we were to have made 9 million BEVs in Japan, it would have actually increased the carbon emissions, not reduced them. That is because Japan relies on thermal power plants for electricity,' Toyoda said. Toyota is one automaker who has been slower to adopt full battery-powered models. Despite selling over 10 million vehicles globally for the past two years, the company has one EV on the market, the bZ4X. Toyota has focused its efforts heavily on hybrids, which made up more than 4.1 million of its sales in 2024 and a mere 139,892 were electric vehicles. In Australia, Toyota sold 115,477 hybrids compared to just 977 EVs, with the RAV4, now available exclusively as a hybrid in Australia, has become the country's best-selling SUV. Toyota's approach to reducing emissions is through a variety of technologies, not just BEVs. 'When the term carbon neutrality became popular, we said as a company the enemy is carbon. We have to focus on what we can do immediately to reduce carbon dioxide. That is the basis of our decision. It has not changed and will not change,' Toyoda said. 'We should look at all options and work in all directions. As a company, we have been very consistent in saying what we're fighting against is carbon dioxide.' Chairman Toyoda also suggested that pivoting too quickly to EVs could endanger jobs, especially in countries like Japan, where engine manufacturing remains a vital part of the economy. While Toyota has begun rolling out EVs across the globe, the pace remains steady. Its EV line-up is limited in comparison to rivals like BYD, Tesla and Hyundai.
ABC News
5 hours ago
- ABC News
AI companion apps such as Replika need more effective safety controls, experts say
The idea of having an emotional bond with a digital character was once a foreign concept. Now, "companions" powered by artificial intelligence (AI) are increasingly acting as friends, romantic partners, or confidantes for millions of people. With woolly definitions of "companionship" and "use" (some people use ChatGPT as a partner, for instance), it's difficult to tell exactly how widespread the phenomenon is. But AI companion apps Replika, Chai and each have 10 million downloads on the Google app store alone, while in 2018 Microsoft boasted its China-based chatbot XiaoIce had 660 million users. These apps allow users to build characters, complete with names and avatars, which they can text or even hold voice and video calls with. But do these apps fight loneliness, or are they supercharging isolation? And is there any way to tip the balance in the right direction? Romance and sexuality are big drawcards to the AI companion market, but people can have a range of other reasons for setting up a chatbot. They may be seeking non-judgemental listening, tutoring (particularly in their language skills), advice or therapy. Bethanie Drake-Maples, a researcher at Stanford University who studies AI companions, says some people also use the apps to reflect their own persona. "Some people will create a digital twin and just have a relationship with an externalised version of themselves," she tells ABC Radio National's series Brain Rot. Ms Drake-Maples published a study based on interviews with more than 1,000 students who used the AI companion app Replika. She and her colleagues found there were important benefits for some users. Most significantly, 30 of the interviewees said using the app had prevented them from attempting suicide. Many participants also reported the app helped them forge connections with other people, through things like advice on their relationships with other people, helping them to overcome inhibitions to connect with others, or by teaching them empathy. But other users reported no benefits, or negative experiences. Outside Ms Drake-Maples' study, AI companions have also been implicated in deaths. Ms Drake-Maples points out their study was a self-selecting cohort, and not necessarily representative of all Replika users. Her team is carrying out a longer-term study to see if they can glean more insights. But she believes it's possible these apps are, on the whole, beneficial for users. "We specifically wanted to understand whether or not Replika was displacing human relationship or whether it was stimulating human relationship," she says. But this social promotion can't be taken for granted. Ms Drake-Maples is concerned that companion apps could replace people's interactions with other humans, making loneliness worse. The participants in her study were much lonelier than the general population, although this isn't necessarily unusual for young college students. She believes governments should regulate AI companion technology to prevent this isolation. "There's absolutely money to be made by isolating people," she says. "There absolutely does need to be some kind of ethical or policy guidelines around these agents being programmed to promote social use, and not being programmed to try to isolate people." Replika says it's introduced a number of controls on its apps to make them safer, including a "Get Help" button that directs people to professional helplines or scripts based on cognitive behavioural therapy, and a message coding system that flags "unsafe" messages and responds in kind. Ms Drake-Maples thinks this is a good example for other apps to follow. "These things need to be mandated across the board," she says. Raffaele Ciriello, a researcher at the University of Sydney, is more sceptical of Replika's safety controls, saying they're "superficial, cosmetic fixes". He points out the controls were introduced months after the Italian government ruled the app had to stop using the data of Italian citizens in early 2023, citing concerns about age verification. "They were fearing a regulatory backlash." Dr Ciriello has also been interviewing and surveying AI companion users, and while he says some users have found benefits, the apps are largely designed for emotional dependence. "If you look at the way [Replika is] making money, they have all the incentives to get users hooked and dependent on their products," he says. Replika operates on a "freemium" model: a free base app, with more features (including the romantic partner option) available by paid subscription. Other companion apps follow the same model. "Replika and their kin have Silicon Valley values embedded in them. And we know what these look like: data, data, data, profit, profit, profit," Dr Ciriello says. Nevertheless, he also believes it's possible for AI companion technology to be built safer and more ethically. Companies that consult vulnerable stakeholders, embed crisis response protocols, and advertise their products responsibly are likely to create safer AI companions. Dr Ciriello says that Replika fails on several of these fronts. For instance, he calls its advertising "deceptive". The company badges its product as "the AI companion who cares". "[But] it's not conscious, it's not actually empathetic, it's not actually caring," Dr Cirello says. A Replika spokesperson said the tagline "the AI companion who cares" was "not a claim of sentience or consciousness." "The phrase reflects the emotionally supportive experience many users report, and speaks to our commitment to thoughtful, respectful design," they said. "In this regard, we are also working with institutions like the Harvard Human Flourishing Program and Stanford University to better understand how Replika impacts wellbeing and to help shape responsible AI development." Dr Ciriello says women-centred Australian app Jaimee is an example of an AI companion with better ethical design — although it faces the "same commercial pressures" as bigger apps in the market. The Californian Senate last week passed a bill regulating AI chatbots. If the bill continues through the legislature to become law, it will — among other things — require the companions to regularly remind users they're not human, and enforce transparency on suicide and crisis data. This bill is promising, Dr Cirello says. "If the history of social media taught us anything, I would rather have a national strategy in Australia where we have some degree of control over how these technologies are designed and what their incentives are and how their algorithms work." But, he adds, research on these apps is still in its infancy, and it will take years to understand their full impact. "It's going to take some time for that research to come out and then to inform sensible legislation." Listen to the full episode about the rise and risks of AI companions, and subscribe to the podcast for more.
News.com.au
a day ago
- News.com.au
GWM's Cannon Alpha Ultra takes aim at the BYD Shark and Ford Ranger PHEV.
We're going to need a bigger boat. Originally established by BYD's Shark in 2024, the new class of plug-in hybrid utes has grown to include Ford's Ranger PHEV and the new GWM Cannon Alpha PHEV. China's GWM promises to split the difference between the affordable, road-biased Shark and Ford's deeply impressive (but similarly expensive) Ranger. Priced from $59,990 plus on-roads (about $63,000 drive-away) for the entry-level version, or $66,990 (about $70,000 drive-away) for the well-appointed Ultra, the Cannon takes the middle ground. Like for like, a GWM with a nice stereo and heated seats costs about $11,000 more than a similarly-specced Shark, or $20,000 less than a loaded Ranger Stormtrak hybrid. First impressions of the Cannon Alpha is that this is a big car – easily a size larger than the Ranger, particularly in the cabin. It looks a little odd, with a long wheelbase that lends unfamiliar proportions. That sense of the strange is amplified by a spare wheel mounted vertically within the tray, as the GWM's underfloor battery means there is no room for a conventional spare wheel. So you can lug it in the tray or leave it at home. But it's luxuriantly spacious on the inside, particularly in a back seat with plenty of legroom. High-end Cannons have a digital dash and head-up display augmented by a 14.6-inch central touchscreen. It has a 10-speaker stereo, wireless charging in the front and rear, and a 360 degree camera with 'see through' tech originally introduced by Land Rover for off-roading. The Cannon is loaded for bear on the luxury front, serving up heated and ventilated seats with a massaging function in the front, along with heated and vented seats with electric adjustment in the rear. While the list of features is extensive, some of the design choices – slabs of shiny fake wood, and a small analog clock – look out of place in 2025. Other head-scratchers include the spare wheel we've already mentioned, and a lack of power points in the cabin or tray. Instead, you have to buy a $230 power board with a special connection that goes into the car's charging port, then plug laptops or power tools into that. It also lacks easily accessible, clearly labelled controls for the hybrid system – most plug-in hybrids make it easier to go EV-only, preserve existing range or add to the battery's charge. More thought went into the Cannon's off-road hardware, which includes separately locking front, rear and centre differentials as well as a nine-speed automatic transmission with a low-range function. That's a great start for an off-roader. Then there's the 2.0-litre turbo petrol engine, a 180kW/380Nm unit that pairs with a 120kW and 400Nm electric motor to make a combined total of 300kW and 750 Nm. Again, those are good numbers. Having driven all three, it feels faster than the Ranger but not as zippy as the Shark – which drives more like a punchy electric vehicle than a hybrid-assisted machine. Other key numbers include a claimed 115km of electric driving range from a 37.1kWh battery that extends to a claimed 1060km of overall range if you fill the petrol tank. GWM claims official fuel use of 1.7L/100km, a figure that – like most plug-in hybrids – is almost impossible to match on the road. Budget on using about 10L/100km in the real world unless towing or off-roading. The Cannon looks set to do a better job of both than the Shark, which can't match its 3.5 tonne towing capacity or off-road hardware. GWM's 800mm of water wading depth and 210mm ground clearance promise decent off-roading performance, though it falls short of the payload claims of its hybrid rivals. Out on the road, GWM's big pickup feels as large as it looks, with relaxed steering and a long wheelbase that lend stability, but make it feel a little unwieldy in town. Soft suspension rides well while returning more roll than you might expect, and there's an occasional delay in throttle responses that can frustrate from time to time. Verdict GWM's Cannon Alpha is an impressive machine that will have people think twice about a conventional ute, but it lacks the star factor of the more affordable Shark or more polished Ranger. GWM Cannon Alpha PHEV WARRANTY: Seven-year, unlimited km THIRST: 1.7L/100km PAYLOAD: 685kg
